盐酸埃克替尼与吉非替尼治疗化疗失败的非小细胞肺癌28例  

Efficacy and toxicity of ecotinib and gefitinib in the treatment for 28 patients with non-small cell lung cancer who have failed previous chemotherapy

作　　者：陈建华[1,2] 罗永忠 王伟[1,2] 周文伟 文小平[1,2] 

机构地区：[1]湖南省肿瘤医院 [2]中南大学湘雅医学院附属肿瘤医院,长沙410013

出　　处：《中国新药杂志》2012年第17期2056-2059,共4页Chinese Journal of New Drugs

摘　　要：目的:探讨盐酸埃克替尼和吉非替尼治疗化疗失败的非小细胞肺癌(NSCLC)的疗效和不良反应。方法:28例NSCLC患者,随机分为试验组和对照组,分别予以盐酸埃克替尼(125 mg,po,tid)和吉非替尼(250 mg,po,qd),观察两组患者的近期疗效和不良反应。结果:试验组14例患者无完全缓解(CR),部分缓解(PR)率21.4%,病情稳定(SD)率35.7%、疾病进展(PD)率28.6%,1例患者因瘫痪退出,1例患者死亡,近期有效率为21.4%,疾病控制率为57.1%。对照组14例患者无CR,PR 7.1%,SD 50%,PD 14.3%,死亡4例,近期有效率为7.1%,疾病控制率为57.1%。两组的近期有效率和疾病控制率、无疾病进展期(PFS)和总生存期(OS)无明显差异。主要不良反应为皮疹,两组比较无显著差异。结论:盐酸埃克替尼与吉非替尼疗效相似,但安全性高,能有效治疗化疗失败的NSCLC。Objective： To evaluate the tients with non-small cell lung cancer who have efficacy and toxicity of gefitinib and ecotinib in the treatment for pafailed previous chemotherapy. Methods： A total of 28 patients were treated with ecotinib orally 125 mg （po, tid） or gefitinib 250 mg （po, qd）. The efficacy and toxicity in the two groups were evaluated. Results： In ecotinib group, no complete regression （CR） was observed, partial response （PR） rate was 21.4% , stable disease （SD） 35.7% , progression of disease （PD） 28.6% ; one patient was rejected due to paralysis and one patient died; response rate was 21.4% and the disease control rate was 57.1%. In gefitinib group, no CR was observed, PR was 7.1% , SD 50% , PD 14.3% ; four patients died; response rate was 7.1% and the disease control rate was 57.1%. There was no significant difference between the two groups in response rate, disease control rate, progression-free survival and the overall survival （OS）. The most common adverse effects were skin reactions in gefitinib group. There was no significant difference in adverse effects between the two treatment groups. Conclusion： The efficacy of ecotinib is similar comparable to that of gefitinib, and the adverse reactions were mild and well tolerated. Ecotinib is suitable and safe for patients with non-small cell lung cancer who have failed previous chemotherapy.

关 键 词：盐酸埃克替尼 吉非替尼 非小细胞肺癌 疗效 不良反应 

分 类 号：R979.1[医药卫生—药品] R969.4[医药卫生—药学]